Model CBM588 - Orally-administered Clostridium Butyricum Strain
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated with dysbiosis of the human gastrointestinal microbiome. CBM588 inhibits certain enteric pathogens and supports colonic homeostasis by producing butyric acid. The strain also possesses novel immunomodulatory activities.
CBM588 is being developed in the U.S. under an IND for prevention of antibiotic associated diarrhea, including Clostridium difficile infection. It is currently being tested in two investigator-sponsored Phase 1 studies at the City of Hope Medical Center to improve clinical outcomes in hematopoietic stem cell transplant and advanced renal cell carcinoma.